Clinical trials: Optimization
Epilepsy, Sudden Cardiac Death
Optimization of VNS in Epileptic Patients to Induce Cardioprotection
This study is a non-randomized, prospective study in patients with a diagnosis of epilepsy and previously implanted FDA approved Vagus Nerve Stimulation (VNS) devices.
- Trial name
- NCT04387435
- Testing
- A change or titration in the current or frequency settings of the VNS therapy system.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of California, Los Angeles
Norovirus Infections
Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines
To evaluate the immunogenicity of VXA-G1.1-NN with repeat-dose administration at Day 1 and varying boost schedules (Week 4, 8 or 12 post initial dose) in healthy adults aged 18-55, inclusive, and to assess the safety and…
- Trial name
- VXA-NVV-105 (NCT04875676)
- Testing
- VXA-G1.1-NN
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Vaxart
ADHD
Efficacy and Safety of SPD503 in Combination With Psychostimulants
The purpose of this study is to assess the efficacy and safety of SPD503 in subjects with ADHD when co-administered with psychostimulants in children and adolescents aged 6-17 years with a diagnosis of ADHD with a sub-optimal…
- Trial name
- NCT00734578
- Testing
- SPD503-AM, SPD503-PM
- Where
- 61 sites in United States
- Volunteers
- 461 people
- Sponsor
- Shire
Type2Diabetes, Pregnancy in Diabetic
AT GOAL: Adopting Technology for Glucose Optimization and Lifestyle in Pregnancy
This study will assess differences in patient preferences and glucose control between continuous glucose monitoring and standard glucose checks in pregnant patients with Type 2 Diabetes.
- Trial name
- NCT05370612
- Testing
- Dexcom G6 CGM, Participant Finger Stick Glucose Monitoring
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Wisconsin, Madison
Psoriasis
Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)
Participants from an ongoing observational study (P05319) who have a limited (adequate but less than optimal) response to infliximab will be randomized to either increase the frequency of infliximab infusions from every 8 weeks…
- Trial name
- DOSE (NCT00833053)
- Testing
- Infliximab, Infliximab and methotrexate
- Volunteers
- 39 people
- Sponsor
- Merck Sharp & Dohme LLC
Cardiac Disease, Dementia
PET-MRI in Diagnosing Patients With Cancer, Cardiac Diseases, or Neurologic Diseases
This randomized pilot clinical trial studies how well positron emission tomography (PET)-magnetic resonance imaging (MRI) works compared to standard-of-care PET-computed tomography (CT) in diagnosing patients with cancer, cardiac…
- Conditions
- Cardiac Disease, Dementia, Inflammatory Disease, Fever of Unknown Origin
- Trial name
- NCT02084147
- Testing
- positron emission tomography, computed tomography, magnetic resonance imaging
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Case Comprehensive Cancer Center
Down Syndrome
Promoting Health Through Parent Empowerment and the Activation of Routines (PrO-PEAR)
This study will examine the feasibility of the Promoting Health through Parent Empowerment and the Activation of Routines (Pro-PEAR) intervention using a open case-series for intervention optimization followed by a pilot RCT in…
- Trial name
- Pro-PEAR (NCT05020366)
- Testing
- Promoting Health through Parent Empowerment and the Activation of Routines, Enhanced Usual Care
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Pittsburgh
Mucopolysaccharidosis I, Hurler's Syndrome
A Dose-optimization Study of Aldurazyme® (Laronidase) in Patients With Mucopolysaccharidosis I (MPS I) Disease
The main purpose of this study is to evaluate differences in the pharmacodynamic response of 4 Aldurazyme® (laronidase) dose regimens in patients with Mucopolysaccharidosis I (MPS I).
- Conditions
- Mucopolysaccharidosis I, Hurler's Syndrome, Hurler-Scheie Syndrome, Scheie Syndrome
- Trial name
- NCT00144781
- Testing
- Aldurazyme (Recombinant Human Alpha-L-Iduronidase)
- Where
- 5 sites in Brazil, Canada
- Volunteers
- 34 people
- Sponsor
- Genzyme, a Sanofi Company
IBS, Constipation
Optimization of Transcutaneous Electrical Acustimulation (TEA) Modalities for Treatment of IBS-C
This study aims to determine the most effective treatment with Transcutaneous Electrical Acustimulation (TEA) for Irritable Bowel Syndrome with Constipation (IBS-C) by comparing efficacy between 5 separate sessions.
- Trial name
- TEA (NCT04953728)
- Testing
- Transcutaneous Electrical Acustimulation (TEA)
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Michigan
Chronotropic Incompetence
The Effect of Blended Sensor Efficiency on Relieving the Heart's Inability to Increase Its Rate During Exercise
The goal of this trial is to test the effect/benefit of a FDA approved blended pacemaker sensor which responds only by comparing physical activity, heart rate, and breathing rate; compared to the accelerometer pacemaker sensor…
- Trial name
- ABSOLVE CI (NCT01619800)
- Testing
- Blended Sensor Optimization (BSO), Accelerometer Alone (AA)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Vivek Reddy
Follicular Lymphoma
Dose Optimization Study of Idelalisib in Follicular Lymphoma
The primary objective of this study is to establish a safe and effective dosing regimen of idelalisib in participants with relapsed or refractory follicular lymphoma (FL) who have no other therapeutic options.
- Trial name
- NCT02536300
- Testing
- Idelalisib
- Where
- 66 sites in Australia, Canada and 8 more
- Volunteers
- 96 people
- Sponsor
- Gilead Sciences
Small Gestational Age (SGA)
Optimization of the Dosage Regimen of Growth Hormone Therapy in Children Born Small for Gestational Age
Multicentric, open-label, randomized, pilot comparative study in parallel groups comparing 1 group of subjects receiving 0.057 milligram/kilogram/day (mg/kg/day) or 0.40 mg/kg/week of Saizen® during 1 year to 1 group receiving…
- Trial name
- SGA OPTIMIS (NCT00249821)
- Testing
- Saizen®
- Volunteers
- 22 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Leukemia, Myeloid, Chronic Phase
Efficacy of 400 Mg Versus 800 Mg Imatinib in Chronic Myeloid Leukemia in Chronic Phase Patients - TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity)
This study investigated the safety and efficacy of 400mg Versus 800mg imatinib in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints.
- Trial name
- TOPS (NCT00124748)
- Testing
- Imatinib mesylate
- Where
- 75 sites in United States, Argentina and 4 more
- Volunteers
- 476 people
- Sponsor
- Novartis Pharmaceuticals
HIV Infections
(mo)BETTA Trial in Transwomen for Optimization of ART
The purpose of this study is to determine the safety and tolerability of a new HIV medication, bictegravir plus emtricitabine plus tenofovir alafenamide (B/FTC/TAF, 3 HIV medications combined into one pill) in HIV-infected…
- Trial name
- (mo)BETTA (NCT03348163)
- Testing
- B/FTC/TAF, Current ART
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- The University of Texas Health Science Center, Houston
Adherence, Treatment, Physical Inactivity
Interrupting Prolonged Sitting With ACTivity (InPACT) at Home Optimization Study
Adherence refers to how well a person follows a recommended and agreed-upon course of action. Adherence is necessary for desired clinical outcomes and can include attending appointments, making lifestyle changes, and following…
- Trial name
- NCT06493214
- Testing
- Physical activity
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- University of Michigan
Attention-deficit/Hyperactivity Disorder
Effectiveness of Vyvanse Compared to Concerta in Adolescents With Attention-deficit/Hyperactivity Disorder
The purpose of this study is to determine effectiveness of Vyvanse compared to Concerta in adolescents with Attention-deficit/Hyperactivity Disorder (ADHD).
- Trial name
- NCT01552915
- Testing
- Lisdexamfetamine dimesylate, Methylphenidate Hydrochloride
- Where
- 79 sites in United States
- Volunteers
- 464 people
- Sponsor
- Shire
Opioid Use, Chronic Pain
Optimization and Multi-Site Feasibility of Yoga for Chronic Pain in People in YOGAMAT-II - Phase II
Phase 2 - Multiphase Optimization Strategy (MOST) Optimization Phase: 1. To conduct a factorial experiment that will allow us to evaluate the impact of each of the 4 intervention components on yoga dosage received.
- Trial name
- YOGAMAT-II (NCT04641221)
- Testing
- Weekly Yoga Classes
- Where
- 2 sites in United States
- Volunteers
- 192 people
- Sponsor
- Butler Hospital
Heart Failure
Heart Failure Optimization at Home to Improve Outcomes (Hozho): A Pragmatic Clinical Trial in Navajo Nation
Heart failure causes significant morbidity and mortality, particularly in Navajo Nation. There are well-established evidence of improved mortality and lower heart failure hospitalizations with certain pharmacotherapies for heart…
- Trial name
- Hozho (NCT05792085)
- Testing
- EHR-based GDMT Optimization
- Where
- 2 sites in United States
- Volunteers
- 103 people
- Sponsor
- University of Pennsylvania
Heart Failure
BOOST - Benefit of Frequent Optimization After Cardiac Resynchronization Therapy Device Replacement
Cardiac resynchronization therapy (CRT) has shown improvement in mortality and morbidity in patients with left ventricular systolic dysfunction and congestive heart failure.
- Trial name
- NCT00929474
- Testing
- QuickOpt - SJM CRT (Group 1), Control - SJM CRT (Group 2)
- Where
- 2 sites in United States
- Volunteers
- 17 people
- Sponsor
- Abbott Medical Devices
Healthy
A Study to Evaluate the Safety and Immunogenicity of IVX-A12 in Participants of 60 to 85 Years of Age
The primary purpose of the study is to assess the safety, tolerability and immunogenicity of a bivalent respiratory syncytial virus (RSV)/human metapneumovirus (hMPV) virus-like particle (VLP) candidate vaccine (IVX-A12) compared…
- Trial name
- NCT05903183
- Testing
- IVX-A12
- Where
- 10 sites in United States
- Volunteers
- 264 people, healthy volunteers welcome
- Sponsor
- Icosavax, Inc.